Cargando…

Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial

OBJECTIVE: To observe the clinical efficacy and safety of the short-term administration of different doses of calcium polystyrene sulfonate in the treatment of hyperkalemia in patients with stage 3–5 non-dialysis chronic kidney disease. METHODS: A prospective, open, randomized, controlled, single-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xia, Chen, Dacheng, Song, Xia, Wang, Jinquan, Zhang, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119845/
https://www.ncbi.nlm.nih.gov/pubmed/37063062
http://dx.doi.org/10.1177/03000605231167516
_version_ 1785029081166774272
author Wang, Xia
Chen, Dacheng
Song, Xia
Wang, Jinquan
Zhang, Haitao
author_facet Wang, Xia
Chen, Dacheng
Song, Xia
Wang, Jinquan
Zhang, Haitao
author_sort Wang, Xia
collection PubMed
description OBJECTIVE: To observe the clinical efficacy and safety of the short-term administration of different doses of calcium polystyrene sulfonate in the treatment of hyperkalemia in patients with stage 3–5 non-dialysis chronic kidney disease. METHODS: A prospective, open, randomized, controlled, single-center clinical observation was conducted. In total, 107 patients were randomly assigned to receive calcium polystyrene sulfonate at 15 (group A) or 30 mg/day (group B) for 1 week. Patients were assessed on days 0, 3, and 7. RESULTS: After 3 days of treatment, the serum potassium levels in groups A and B had decreased by 0.68 ± 0.46 and 0.75 ± 0.43 mmol/L, respectively. After 7 days, the serum potassium levels in groups A and B had decreased by 0.64 ± 0.37 and 0.94 ± 0.49 mmol/L, respectively. Conversely, serum sodium, phosphorus, and calcium levels did not significantly change during the treatment period. Constipation was the most common adverse drug reaction, and no treatment-related serious adverse events were observed. CONCLUSION: Calcium polystyrene sulfonate administered at a dose of 15 or 30 g/day can rapidly reduce potassium levels in patients with stage 3–5 non-dialysis chronic kidney disease without adverse effects on sodium, phosphorus, or calcium levels.
format Online
Article
Text
id pubmed-10119845
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-101198452023-04-22 Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial Wang, Xia Chen, Dacheng Song, Xia Wang, Jinquan Zhang, Haitao J Int Med Res Prospective Clinical Research Report OBJECTIVE: To observe the clinical efficacy and safety of the short-term administration of different doses of calcium polystyrene sulfonate in the treatment of hyperkalemia in patients with stage 3–5 non-dialysis chronic kidney disease. METHODS: A prospective, open, randomized, controlled, single-center clinical observation was conducted. In total, 107 patients were randomly assigned to receive calcium polystyrene sulfonate at 15 (group A) or 30 mg/day (group B) for 1 week. Patients were assessed on days 0, 3, and 7. RESULTS: After 3 days of treatment, the serum potassium levels in groups A and B had decreased by 0.68 ± 0.46 and 0.75 ± 0.43 mmol/L, respectively. After 7 days, the serum potassium levels in groups A and B had decreased by 0.64 ± 0.37 and 0.94 ± 0.49 mmol/L, respectively. Conversely, serum sodium, phosphorus, and calcium levels did not significantly change during the treatment period. Constipation was the most common adverse drug reaction, and no treatment-related serious adverse events were observed. CONCLUSION: Calcium polystyrene sulfonate administered at a dose of 15 or 30 g/day can rapidly reduce potassium levels in patients with stage 3–5 non-dialysis chronic kidney disease without adverse effects on sodium, phosphorus, or calcium levels. SAGE Publications 2023-04-16 /pmc/articles/PMC10119845/ /pubmed/37063062 http://dx.doi.org/10.1177/03000605231167516 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Prospective Clinical Research Report
Wang, Xia
Chen, Dacheng
Song, Xia
Wang, Jinquan
Zhang, Haitao
Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial
title Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial
title_full Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial
title_fullStr Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial
title_full_unstemmed Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial
title_short Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial
title_sort efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial
topic Prospective Clinical Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119845/
https://www.ncbi.nlm.nih.gov/pubmed/37063062
http://dx.doi.org/10.1177/03000605231167516
work_keys_str_mv AT wangxia efficacyandsafetyofcalciumpolystyrenesulfonateinpatientswithhyperkalemiaandstage35nondialysischronickidneydiseaseasinglecenterrandomizedcontrolledtrial
AT chendacheng efficacyandsafetyofcalciumpolystyrenesulfonateinpatientswithhyperkalemiaandstage35nondialysischronickidneydiseaseasinglecenterrandomizedcontrolledtrial
AT songxia efficacyandsafetyofcalciumpolystyrenesulfonateinpatientswithhyperkalemiaandstage35nondialysischronickidneydiseaseasinglecenterrandomizedcontrolledtrial
AT wangjinquan efficacyandsafetyofcalciumpolystyrenesulfonateinpatientswithhyperkalemiaandstage35nondialysischronickidneydiseaseasinglecenterrandomizedcontrolledtrial
AT zhanghaitao efficacyandsafetyofcalciumpolystyrenesulfonateinpatientswithhyperkalemiaandstage35nondialysischronickidneydiseaseasinglecenterrandomizedcontrolledtrial